Granted Patent B2

US 9,951,317 · App. 15/287,433 · Granted Apr 24, 2018

Inventors: Gale Smith (Gaithersburg, MD); Yingyun Wu (Clarksburg, MD); Michael J. Massare (Mt. Airy, MD); Peter M. Pushko (Frederick, MD); Margaret Nathan (Montgomery Village, MD); Thomas Kort (Germantown, MD); Robin Robinson (Gaithersburg, MD)

Assignee: NOVAVAX, INC.

C12N7/00A61K39/12C07K14/005C12N9/2402C12Y302/01018A61K2039/5258A61K2039/55505A61K2039/55555C07K2319/01C07K2319/03C12N2710/14143C12N2760/16122C12N2760/16123C12N2760/16134C12N2760/16151C12N2760/16171C12N2760/16222C12N2760/16223C12N2760/16251C12N2770/20022C12N2770/20023C12N2770/20051C12N2800/22

Abstract

Claims (20)

1. A virus-like particle (VLP) comprising influenza proteins wherein the influenza proteins consist of an influenza M1 protein and an influenza neuraminidase (NA) protein, wherein said M1 protein comprises the amino acid residues YKKL at the positions corresponding to positions 100-103 of SEQ ID NO: 49, wherein the VLP is produced in an Sf9 cell.

2. The VLP of claim 1 , wherein said influenza M1 protein is derived from an avian influenza virus strain.

3. The VLP of claim 2 , wherein said avian influenza virus strain is A/Indonesia/5/05.

4. The VLP of claim 1 , wherein said neuraminidase (NA) protein is from a different influenza strain than the M1 protein.

5. The VLP of claim 1 , wherein said NA protein is derived from an avian influenza virus.

6. The VLP of claim 5 , wherein said avian influenza virus is an H5N1 subtype.

7. The VLP of claim 5 , wherein said avian influenza virus is an H9N2 subtype.

8. The VLP of claim 1 , wherein said NA protein is derived from a seasonal influenza virus.

9. The VLP of claim 8 , wherein said seasonal influenza virus is a type A influenza virus.

10. The VLP of claim 8 , wherein said seasonal influenza virus is a type B influenza virus.

11. The VLP of claim 1 , wherein said NA exhibits neuraminidase activity.

12. The VLP of claim 1 , wherein said NA protein is a chimeric protein.

13. The VLP of claim 12 , wherein said chimeric protein comprises external domains of non-avian influenza NA protein sequences fused to the transmembrane and/or cytoplasmic terminal domains of the avian NA.

14. The VLP of claim 13 , wherein said non-avian influenza NA is from influenza strain A/Wisconsin/67/2005 and said avian influenza NA is from influenza strain A/Indonesia/5/05.

15. A method of increasing the efficiency of VLP production comprising expressing an influenza M1 protein and an influenza neuraminidase (NA) protein in an Sf9 cell, wherein said M1 protein comprises the amino acid residues YKKL at the positions corresponding to positions 100-103 of SEQ ID NO: 49, wherein the VLP comprises influenza proteins consisting of the influenza M1 protein and the influenza NA protein.

16. The method of claim 15 , wherein said influenza M1 protein is derived from an avian influenza virus strain.

17. The method of claim 16 , wherein said avian influenza virus strain is A/Indonesia/5/05.

18. The method of claim 15 , wherein said neuraminidase (NA) protein is from a different influenza strain than the M1 protein.

19. The VLP of claim 18 , wherein said NA protein is derived from a seasonal influenza virus.

20. A vaccine comprising the VLP of claim 1 .

Assignments (2)

Continuity (17)